We are monitoring the impact of COVID-19 on Europe Cancer Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 158
Share on
Share on

European Cancer Monoclonal Antibodies Market Research Report – Segmented By Application, By Type, By Conjugated Cancer Therapies & By Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Global Industry Analysis, Size, Share, Growth, Trends, Forecast (2019-2024)

Pulished: February, 2020
ID: 158
Pages: 120

Europe Cancer Monoclonal Antibodies Market Size & Growth (2019 - 2024)

The size of the Cancer Monoclonal Antibodies Market in Europe is a USD 14.11 billion market in 2019 and is estimated to reach USD 23.24 billion by 2024 with a growth rate of 10.9%.

Rising prevalence for the targeted therapeutic procedures is a key driving factor for the market to grow extensively. Increasing incidences of chronic diseases is another common attribute for the market to grow in Europe. Besides, escalating expenditure on healthcare is lavishing the growth rate of the cancer monoclonal antibodies market. Growing awareness over the development of innovative drugs is greatly influencing the demand of the market. As cancer is being the main cause of the number of deaths, the demand for treatment of cancer with monoclonal antibodies is leveraging the growth rate of the market. The rising scale of research centers is also promoting the demand for this market.

However, stringent rules and regulations by the government in approving new products are straightly hindering the growth rate of the market. Fluctuations in the availability of raw materials and increasing prices of final products are slowly restricting the growth rate of the market. Lack of skilled professionals in manufacturing drugs with the latest technology remains a challenging factor for the market.

Changes in government schemes and the launch of reimbursement policies in favor of the common people are anticipated to present growth opportunities for the market. An increasing number of healthcare centers are also one of the factors accelerating the demand of the Europe cancer monoclonal antibodies market. Growing awareness over the availability of various diagnostic and treatment procedures is greatly influencing the demand of the market.

This research report segmented and sub-segmented into the following categories:

  • By Application: Liver, Breast, Blood, Brain, Hodgkin’s And Non-Hodgkin’s Lymphoma, Colorectal, Leukaemia, and Others
  • By Type: Murine Antibodies, Chimeric & Humanised Antibodies, Fully Humanized Antibodies
  • By Conjugated Cancer Therapies: Immunoliposome, Radioimmunotherapy, ADEPT, Immunocytokines, Others
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

Geographically, the cancer monoclonal antibodies market in Europe is having a tremendous growth rate from the past few years. Among all, the United Kingdom is leading with the largest shares of the market with the increasing economic status. Italy and Germany are next to the United Kingdom in holding the highest shares by owing to the adoption of the latest technological developments in the medical sector. Spain and the Rest of Europe are inclined to have leading shares in the forecast period.

Top companies in the market

Notable companies leading the European Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, GlaxoSmithKline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis & Spectrum Pharmaceuticals.

  1. Introduction

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods          

                1.4 General Study Assumptions

  1. Research Methodology

                2.1 Introduction               

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

  1. Overview

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 New Developments               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market              

  1. Market Segmentation

                5.1 By Application           

                                5.1.1 Liver

                                5.1.2 Breast

                                5.1.3 Brain

                                5.1.4 Blood

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma

                                5.1.6 Colorectal

                                5.1.7 Leukaemia

                                5.1.8 Others

                5.2 By Type        

                                5.2.1 Murine Antibodies

                                5.2.2 Chimeric and Humanised Antibodies

                                5.2.3 Fully Humanized Antibodies

                5.3 Conjugate Cancer Therapies               

                                5.3.1 Immunoliposome

                                5.3.2 Radioimmunotherapy

                                5.3.3 ADEPT

                                5.3.4 Immunocytokines

                                5.3.5 Others

  1. Geographical Analysis

                6.1 Introduction               

                6.2 U.K 

                6.3 Spain             

                6.4 Germany     

                6.5 Italy               

                6.6 France          

  1. Strategic Analysis

                7.1 PESTLE analysis         

                                7.1.1 Political

                                7.1.2 Economic

                                7.1.3 Social

                                7.1.4 Technological

                                7.1.5 Legal

                                7.1.6 Environmental

                7.2 Porter’s Five analysis              

                                7.2.1 Bargaining Power of Suppliers

                                7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry

  1. Market Leaders' Analysis

                8.1 Roche

                                8.1.1 Overview

                                8.1.2 Product Analysis

                                8.1.3 Strategic Evaluation and Operations

                                8.1.4 Financial analysis

                                8.1.5 Legal issues

                                8.1.6 Recent Developments

                                8.1.7 SWOT analysis

                                8.1.8 Analyst View

                8.2 Amgen

                8.3 Genmab

                8.4 Glaxosmithkline

                8.5 Bristol Meyer Squibb

                8.6 Eli Lilly

                8.7 Immunogen

                8.8 Novartis

                8.9 Seattle Genetics

                8.10 Spectrum Pharmaceuticals

  1. Competitive Landscape

                9.1 Market share analysis            

                9.2 Merger and Acquisition Analysis       

                9.3 Agreements, collaborations and Joint Ventures         

                9.4 New Product Launches         

  1. Expert Opinions

                10.1 Market Outlook     

                10.2 Investment Opportunities 

     Appendix                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Cancer Monoclonal Antibodies Market By Region, From 2019-2024 ( USD Million )
  2. Europe Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  3. Europe Liver Market By Region, From 2019-2024 ( USD Million )
  4. Europe Breast Market By Region, From 2019-2024 ( USD Million )
  5. Europe Brain Market By Region, From 2019-2024 ( USD Million )
  6. Europe Blood Market By Region, From 2019-2024 ( USD Million )
  7. Europe Hodgkins and Non-Hodgkins lymphoma Market By Region, From 2019-2024 ( USD Million )
  8. Europe Colorectal Market By Region, From 2019-2024 ( USD Million )
  9. Europe Leukaemia Market By Region, From 2019-2024 ( USD Million )
  10. Europe Others Market By Region, From 2019-2024 ( USD Million )
  11. Europe Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  12. Europe Murine Antibodies Market By Region, From 2019-2024 ( USD Million )
  13. Europe Chimeric and Humanised Antibodies Market By Region, From 2019-2024 ( USD Million )
  14. Europe Fully Humanized Antibodies Market By Region, From 2019-2024 ( USD Million )
  15. Europe Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  16. Europe Immunoliposome Market By Region, From 2019-2024 ( USD Million )
  17. Europe Radioimmunotherapy Market By Region, From 2019-2024 ( USD Million )
  18. Europe ADEPT Market By Region, From 2019-2024 ( USD Million )
  19. Europe Immunocytokines Market By Region, From 2019-2024 ( USD Million )
  20. Europe Others Market By Region, From 2019-2024 ( USD Million )
  21. Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  22. Liver Market By Region, From 2019-2024 ( USD Million )
  23. Breast Market By Region, From 2019-2024 ( USD Million )
  24. Brain Market By Region, From 2019-2024 ( USD Million )
  25. Blood Market By Region, From 2019-2024 ( USD Million )
  26. Hodgkins and Non-Hodgkins lymphoma Market By Region, From 2019-2024 ( USD Million )
  27. Colorectal Market By Region, From 2019-2024 ( USD Million )
  28. Leukaemia Market By Region, From 2019-2024 ( USD Million )
  29. Others Market By Region, From 2019-2024 ( USD Million )
  30. U.K. Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  31. U.K. Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  32. U.K. Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  33. Germany Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  34. Germany Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  35. Germany Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  36. France Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  37. France Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  38. France Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  39. Italy Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  40. Italy Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  41. Italy Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )
  42. Spain Cancer Monoclonal Antibodies Market By Application, From 2019-2024 ( USD Million )
  43. Spain Cancer Monoclonal Antibodies Market By Type, From 2019-2024 ( USD Million )
  44. Spain Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2019-2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample